Phaseline

Targets › TCR

TCR: drug programs, companies and trials

1 program from 1 company in 3 trials: 3 Phase 2; Oncology; next expected readout Oct 2027.

Open in Phaseline: the race on TCR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Young TIL
T cell receptor (TCR)-engineered tumor infiltrating lymphocytes (TIL) therapy
TCRPhase 2Advanced Non-Small Cell Lung Cancer; Melanoma; Metastatic Colorectal CancerOct 2027

Conditions

Advanced Non-Small Cell Lung Cancer (1) Melanoma (1) Metastatic Colorectal Cancer (1)

Modalities

mixed (1)

Companies

National Cancer Institute (NCI) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.